Management of Chemotherapy-Induced Nausea and Vomiting

Indian Pediatrics

Volumn 47, Issue 2, 2010, Pages 149-155

  Dewan, Pooja ^a   Singhal, Swati ^b   Harit, Deepika ^a  

^a UCMS AND GTB HOSPITAL   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Antiemetics; Cancer; Chemotherapy; Nausea; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARMUSTINE; CASOPITANT; CHLORMETHINE; CISAPRIDE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DRONABINOL; FOSAPREPITANT; GRANISETRON; IFOSFAMIDE; L 758 298; LEVONANTRADOL; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; NABILONE; NETUPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PIMOZIDE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILDHOOD CANCER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPHORIA; EPIGASTRIC BURNING; FATIGUE; FLUSHING; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOTENSION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; VEIN DISEASE;

ADOLESCENT; ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NAUSEA; VOMITING;

EID: 76649084887     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: 10.1007/s13312-010-0023-4     Document Type: Review

References (23)

1. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present and future recommendations. Oncologist 2007; 12: 1143-1150.
2. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947.
3. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005; 13: 117-121.
4. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002; 10: 88-95.
5. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008; 4: 85-93.
6. Schwartberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology (Williston Park) 2007; 21: 946-953.
7. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005; 41: 199-205.
8. Antonarakis ES, Hain RDW. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and practice. Arch Dis Child 2004; 89: 877-880.
9. Sarcev T, Secen N, Zaric B, Milovancev A. Aprepitant - where do we stand in the control of chemotherapy-induced nausea and vomiting? J BUON 2008; 13: 333-339.
10. Oechsle K, Müller MR, Hartmann JT, Kanz L, Bokemeyer C. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone. Onkologie 2006; 29: 557-561.
11. Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 2008; 113: 529-535.
12. Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, et al. Anti-emetic efficacy of the neurokinin-1 antagonist, aprepitant, plus 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high dose cisplatin: analysis of combined data from two phase III randomized controlled clinical trials. Cancer 2005; 15; 104: 864-868.
13. Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006; 14: 354-360.
14. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-1006.
15. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008; 112: 2080-2087.
16. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005; 45: 857-860
17. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009; 52: 242-247.
18. Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008; 14:157-162.
19. Navari RM. Fosaprepitant (MK-0517): A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2007; 16: 1977-1985.
20. Olver IN. Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag 2008; 4: 501-506.
21. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004; 64: 1125-1132.
22. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009; 17: 589-594.
23. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006; 4: 403-408.